Jazz Pharmaceuticals (JAZZ) Up Ahead of Phase III Study Presentation
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is 7% higher this morning after announcing that data from its first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented next week (October 20) during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress in Las Vegas, Nevada.
Jazz Pharmaceuticals has completed two Phase III pivotal clinical trials of JZP-6, with positive results in both studies. Jazz Pharmaceuticals is working to submit a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009.
Jazz Pharmaceuticals has completed two Phase III pivotal clinical trials of JZP-6, with positive results in both studies. Jazz Pharmaceuticals is working to submit a New Drug Application for sodium oxybate for the treatment of fibromyalgia to the U.S. Food and Drug Administration by the end of 2009.
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Jazz Pharmaceuticals (JAZZ) at Outperform
- OmniVision (OVTI) Volatility Up on Move Lower
- A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human Genome Sciences
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
